Find Your Daily Voice
Mamaroneck
Larchmont
Your Local News for Mamaroneck and Larchmont, New York
Friday, dec 27
35°
Follow
News
Schools
Business
Obituaries
Police & Fire
Weather
Lifestyle
Politics
Sports
Traffic
Real Estate
Tags
Jobs
Shop
Support Us
Mamaroneck
Larchmont
Follow
Find Your Daily Voice
News
Schools
Business
Obituaries
Police & Fire
Weather
Lifestyle
Politics
Sports
Traffic
Real Estate
Tags
Jobs
Shop
Support Us
Home
About us
All sites
Advertise with us
Contact us
Terms of use
Privacy policy
Code of ethics
Site Map
© 2024 Cantata Media
35°
Friday, dec 27
Tag:
Stéphane Bancel
News
Covid-
19: Updated Vaccine Boosts Protection Against Omicron, Moderna Says
Biotechnology company Moderna announced its goal to release an updated booster vaccine this summer after data analysis showed the booster's superior protection against the Omicron variant compared to its original vaccine. The company said in an announcement on Wednesday, June 8, that data analysis shows that its Omicron-containing bivalent COVID vaccine shows superior neutralizing antibody response against Omicron one month after administration compared to its original vaccine. Moderna said the side effects of the new booster dose are comparable to a booster dose of its original …
News
Covid-
19: Moderna Seeks Vaccine Authorization For Kids Under Age 6
Moderna says it has submitted a request to the Food and Drug Administration for emergency use authorization of its COVID-19 vaccine for children younger than 6. The company made the announcement on Thursday, April 28, saying it submitted a request to FDA to authorize its vaccine for children from ages 6 months to 6 years old. Moderna's vaccines are currently only authorized for individuals aged 18 and older. "We are proud to share that we have initiated our EUA submission for authorization for our COVID-19 vaccine for young children," Moderna CEO Stéphane Bancel said. "We believe mRNA-1273…
News
Covid-
19: Moderna Vaccine Gets Full Approval From FDA
Federal officials have granted full approval to Moderna’s COVID-19 vaccine following its authorization last year for emergency use. On Monday, Jan. 31, the Food and Drug Administration (FDA) announced that Moderna’s vaccine has been granted its full approval, joining the Pfizer shot which was authorized months ago. The move comes after tens of millions of doses of the Moderna vaccine have already been administered across the country. It also represents Moderna’s first FDA-approved product in the US. Officials said the FDA reviewed months of additional follow-up data submitted by Moderna to…
News
Covid-
19: Pfizer CEO Announces When Vaccine Targeting Omicron Variant Will Be Ready
A vaccine targeting the highly transmissible Omicron COVID-19 variant could be on the way from Pfizer. On Monday, Jan. 10, Pfizer CEO Albert Bourla said that booster targeting Omicron will be ready as soon as March, as the company has already begun ramping up production of the doses. “This vaccine will be ready in March,” Bourla told CNBC’s “Squawk Box.” “We (are) already starting manufacturing some of these quantities at risk.” Related story - COVID-19: Fauci Offers New Prediction On When Omicron Wave May Break The vaccine will not exclusively target Omicron, but will also be able to fig…
News
Covid-
19: Here's When Fourth Shot May Be Needed, Moderna CEO Says
The chief executive officer of Moderna has gone on record saying when another round of COVID-19 vaccine booster shots could be required. Moderna CEO Stephane Bancel said this week that due to the efficacy of the vaccine potentially waning over time, a fourth booster could be required before the fall of 2022. Bancel made the proclamation at a Goldman-Sachs-organized healthcare conference, noting that his company is working on a booster shot dedicated to combating the Omicron variant of the virus, which will likely be made available within the next two months. According to recent studies, bo…
News
Covid-
19: Booster Shot Significantly Raises Antibody Levels Against Omicron, Moderna Says
A Moderna COVID-19 vaccine booster shot significantly raises the level of antibodies against the new Omicron variant, the company announced on Monday morning, Dec. 20. The currently authorized 50-microgram booster neutralized antibody levels against Omicron approximately 37-fold compared to pre-boost levels and a 100-micrograms dose increased neutralizing antibody levels approximately 83-fold compared to pre-boost levels, the Cambridge, Massachusetts-based company said in a statement. The results are based on laboratory testing. “The dramatic increase in COVID-19 cases from the O…
News
Covid-
19: FDA Clears Moderna, Pfizer Boosters For All US Adults
Federal health officials have given the green light for all Americans to get COVID-19 booster shots for all adults. The Food and Drug Administration (FDA) authorized Moderna and Pfizer COVID-19 booster shots for all adults in the US 18 and older, paving the way for expanding the eligibility of boosters in advance of the holiday season. Previously, the FDA had only authorized booster shots for Americans 65 and older, and those who were at a high risk of contracting COVID-19 due to pre-existing conditions of their job. “Authorizing the use of a single booster dose of either the Moderna or Pf…
News
Covid-
19: Moderna Vaccine Safe, Effective For Children Ages 6 To 11, Company Says
Moderna has declared that its two-dose COVID-19 vaccine is safe and has produced a strong antibody response in children between the ages of 6 and 11. A new study of children in that age group found that the vaccine is safe to administer 28 days apart, according to the company and National Institutes of Health, which used shots with a 50 microgram dose of the vaccine, half the dosage for adults. In total, nearly 5,000 children participated in the study, the results of which were announced in a press release, but have yet to be peer-reviewed or published in a journal. The most common side …
News
Covid-
19: Studies Determine How Effective Moderna Vaccine Is Six Months After Second Dose
The Moderna COVID-19 vaccine has proven to be largely effective six months after Americans receive a second dose, according to recent studies conducted by the pharmaceutical company. Moderna CEO Stéphane Bancel announced this week that the latest round of studies into the vaccine found that it maintains 93 percent of its efficacy six months after the second dose is administered. Bancel said that while the vaccine remains effective, it is important to recognize the threat of variants of the virus, specifically the more transmissible Delta variant, which has been rapidly spreading across the …
News
Covid-
19: New Study Reveals How Long Protection From Pfizer, Moderna Vaccines Could Last
Claims that booster shots could be required in several months for those receiving the Moderna and Pfizer COVID-19 vaccine may have been overblown, according to new reports. New findings in a study published this week showed that both COVID-19 vaccines have shown a “persistent” immune response to the virus that could potentially last years. The last looming question is how effective the vaccines are against variants of the virus, specifically the more transmissible Delta strain that has become dominant in the US and is present in 49 states. Related story - COVID-19: Parts Of US With Low Va…
News
Covid-
19: Moderna Asks FDA To Approve Vaccines For Those Ages 12 To 17
Moderna has requested an emergency use authorization from the Food and Drug Administration (FDA) for its COVID-19 vaccine in adolescents between the ages of 12 and 17. The company announced that clinical trials have shown that the vaccine has a 93 percent efficacy rate among adolescents, and has been proven to be safe. If approved, it would be the second COVID-19 vaccine authorized for adolescents, joining the Pfizer-BioNTech vaccine, which was given the green light for use earlier this month. In their study, Moderna found no cases of COVID-19 in participants who received two doses of th…
News
Covid-
19: Vaccine 'Safe, Highly Effective' In Kids 12-17, Moderna Says, Will Seek FDA Approval
Moderna’s COVID-19 vaccine has proven effective and safe for adolescents and teens between the ages of 12 and 17, the company announced, as it prepares to seek federal authorization. The company announced that clinical trials have shown that the vaccine has a 93 percent efficacy rate among adolescents, and has been proven to be safe. Moderna officials said that they plan to apply for federal approval from the Food and Drug Administration (FDA) to use the vaccine in that age group in June. If approved, it would be the second COVID-19 vaccine authorized for adolescents, joining the Pfizer-Bi…
Business
Covid-
19: Moderna Will Double Size Of Vaccine Manufacturing Space
With the goal of producing billions of COVID-19 vaccine doses by the end of 2022, Moderna announced that it will be expanding its production facility, located in New England. The biotechnology company, which is currently one of three companies that have been granted emergency use authorization to produce COVID-19 vaccines in the United States (along with Pfizer and Johnson & Johnson), announced that it will be doubling the size of the Moderna Technology Center in Norwood, Massachusetts. According to the company, the expansion includes an increase of the company’s production and lab spac…
News
Covid-
19: Pfizer, Moderna Release Clinical Trial Results On Response Against Virus Variants
Both Pfizer and Moderna - two of the three COVID-19 vaccines approved for distribution in the US - have seen promising results in combating variants of the virus in recent studies. This week, both pharmaceutical companies released results of clinical trials that show the vaccines are effective in combating COVID-19 variants, including the prominent strains from South Africa and Brazil. Moderna has been testing a 50-microgram dose of its vaccine in previously vaccinated people, which found the booster dose increased neutralizing antibody responses against the original virus as well as the va…
News
Covid-
19: Moderna Announces How Long Vaccine Can Be Stored, How Many Doses It Will Make In 2022
New data has found that the Moderna COVID-19 vaccine vials will maintain its efficacy and stability for several months if it is properly stored at temperatures found in refrigerators. Currently, the vaccine is approved to be stored in a refrigerator between 36 and 46 degrees Fahrenheit for up to 30 days and up to seven months at minus 4 Fahrenheit. However, new data from Moderna found that it could support a three-month refrigerated shelf life that could “facilitate easier distribution to doctor’s offices and other smaller settings” if authorized by the Food and Drug Administration (FDA). …
News
Covid-
19: Moderna Seeks Full FDA Approval For Vaccine
With six months having passed since Moderna began clinical trials for its COVID-19 vaccine, the pharmaceutical company is seeking full approval from the Food and Drug Administration. Moderna, which currently has emergency use authorization from the FDA to distribute its vaccine, reported in its latest trial data that it has proven 90 percent effective in preventing the symptoms of COVID-19, and 95 percent effective in the most severe cases of the virus. Currently, no COVID-19 vaccine is fully approved by the FDA, but three - Moderna, Pfizer, and the currently questionable Johnson & John…
News
Covid-
19: Moderna Announces When Booster Shot Will Be Available For Those Who Got Two Doses
Moderna is working on a booster shot for its two-dose COVID-19 vaccine that will be made available by the fall to help avoid another surge of new cases over the winter. CEO Stephane Bancel said on CNBC that the company “wants to make sure there are boost vaccines available in the fall so that we protect people as we go into the next fall and winter season in the U.S.” Last month, the National Institutes of Health began testing several versions of boosters from Moderna that could potentially be used to combat variants of COVID-19, including the South African strain that has flummoxed resear…
News
Covid-
19: FDA Approves Changes To Moderna Vaccine
The Food and Drug Administration has approved changes to the Moderna COVID-19 vaccine. On Thursday, April 1, the FDA announced that it has ruled that Moderna can put 50 percent more vaccine dosages in each vial, moving from 10 doses each to 15, which will allow for a more expeditious rollout of the vaccine. The FDA is also allowing 11 doses to be extracted out of the current 10 dose vials. Additionally, the FDA authorized the Moderna vaccine to be kept at room temperature conditions once removed from the refrigerator for administration for 24 hours, an increase from the previous 12 hours. …
News
Covid-
19: Moderna Begins Vaccine Trials For Children, Babies
Moderna is moving forward with its latest COVID-19 vaccine trial, testing it in children six months to less than 12 years old as the company reviews the effectiveness and safety of the shot in younger Americans. As part of the study, researchers will be giving two injections 28 days apart of either the Moderna vaccine or a placebo, to the children being tested. The current Moderna vaccine has only been authorized for use in those 18 and older. Kids who get the vaccine will receive one of three possible doses, from 25 micrograms up to 100 micrograms – the same dose that received an emergen…
35°
